Tumour Necrosis Factor-α Promoter Polymorphism in Erythema Nodosum

SVENJA LABUNSKI1, GUIDO POSERN2, STEPHAN LUDWIG2, G. KUNDT3, EVA-B. BRÖCKER1 and MANFRED KUNZ4

Departments of Dermatology, 1University of Würzburg, Würzburg and 4University of Rostock, Rostock; 2Institut für Medizinische Strahlenkunde und Zellforschung, Würzburg, 3Institute for Medical Informatics and Biometry, University of Rostock, Germany

Erythema nodosum is a common skin disease characterized by erythematous, tender subcutaneous nodules, mostly located on the lower extremities. Little is known about its pathogenesis, although a wide variety of aetiological factors (e.g. bacterial and viral infections, neoplastic diseases and drugs) have been described. Sarcoidosis, a typical granulomatous disease, often occurs in association with erythema nodosum (Loefgren syndrome). Since granulomatous diseases have been closely linked to a deregulated tumour necrosis factor (TNF)-α production, it was tempting to speculate whether TNF-α might play a role in the pathogenesis of erythema nodosum, at least in cases associated with sarcoidosis. A previously described nucleotide exchange, (G→A) at position −308 in the human TNF-α gene promoter, has been shown to be a major cause for enhanced TNF-α production. In the present report, we investigated the genomic TNF-α promoter region in patients suffering from EN with and without underlying sarcoidosis. Our results showed a strong correlation between the uncommon TNF A II allele and sarcoidosis-associated erythema nodosum. Patients with erythema nodosum without underlying sarcoidosis displayed a similar allele frequency compared with controls. Taken together, we provide evidence that erythema nodosum in association with sarcoidosis might be pathogenically linked to altered TNF-α production due to a genetic promoter polymorphism. Key words: erythema nodosum; TNF-α promoter polymorphism.

(Accepted January 3, 2001.)

Acta Derm Venereol 2001; 81: 18–21

Manfred Kunz, Department of Dermatology and Venereology, University of Rostock, Augusten-Straße 80, 18055 Rostock.
E-mail: manfred.kunz@med-uni-rostock.de

Erythema nodosum (EN) is a common skin disease characterized by erythematous, tender subcutaneous nodules, mostly located on the anterior aspects of the lower extremities (1). Lesions usually resolve spontaneously within a few weeks without ulceration or scarring. However, cases without a tendency to self-healing occur and recurrences are a common feature. The onset of lesions is often accompanied by malaise, fever, chills and leukocytosis. Arthopathy and episcleral involvement may be associated with the cutaneous signs. Although association with a variety of diseases has been described, up to now, little is known about the pathogenesis of EN. Diseases that have been linked to EN are sarcoidosis, inflammatory bowel disease, malignancies and bacterial (streptococcal infections, tuberculosis), viral and fungal infections (2). There are also some cases attributed to drugs, e.g. sulfonamides and oral contraceptives (2). Most commonly EN occurs after streptococcal infections and sarcoidosis, a typical granulomatous disease. Sarcoidosis-associated EN had been termed Loefgren syndrome. Loefgren syndrome is characterized by the acute exacerbation of sarcoidosis with bihilar adenopathy, fever, arthopathy and EN.

TNF-α is an important mediator of a wide variety of immunological and inflammatory reactions (3, 4). The TNF-α gene locus is located in the class III region of the major histocompatibility complex (MHC) on the short arm of chromosome 6 (5). A genetic biallelic polymorphism has been described at position −308 of the human TNF-α promoter consisting of the alleles TNFAI (guanine at position −308) and TNFAII (adenine at the position −308) (6). It has been shown that this polymorphic variation within in the promoter region exerts influence on TNF-α production. The TNF A II promoter shows significantly enhanced responsiveness after appropriate stimulation compared with the more common TNF A I promoter (7, 8). Based on these findings, it was tempting to speculate that carriers of the TNF A II allele might be prone to a more severe outcome of inflammatory diseases and might even be susceptible to autoimmune disorders, due to enhanced TNF production. The second hypothesis was fuelled by an association of the TNF promoter polymorphism with specific HLA alleles (9, 10). Indeed, increased allele frequencies of the TNF A II gene were described in patients with severe infectious diseases, such as cerebral malaria (11) and mucocutaneous leishmaniasis (12), and in some autoimmune disorders, such as lupus erythematosus (13) and diabetes mellitus (14).

TNF-α is mainly produced by activated macrophages (3) and it has also been shown to play an essential role in granuloma formation (15, 16). During granuloma formation TNF-α is required for accumulation of macrophages and differentiation of macrophages into epitheloid cells. The presence of TNF-α is important for both the induction and persistence of well-developed granulomas (16).

In the present report, we addressed the question of whether a TNF-α promoter polymorphism plays a role in the pathogenesis of the acute exacerbation of sarcoidosis presenting as Loefgren syndrome. Our data described a clear association of the uncommon TNF A II allele with this disease while EN of other aetiology showed no association.

MATERIALS AND METHODS

To address the question of whether a −308 TNF-α promoter polymorphism correlates with sarcoidosis-associated EN or EN of other aetiology we compared allele frequencies and genotype distribution defined by NcoI polymorphism in patients suffering from EN and...
pulmonary sarcoidosis (Loefgren syndrome) with a group of patients suffering from non-sarcoidosis-associated EN.

Patients

Genomic DNA of 37 age- and sex-matched patients was analysed. Ten patients suffered from EN without underlying sarcoidosis, 10 patients suffered from EN and pulmonary sarcoidosis. Five patients suffering from granuloma annulare and 12 patients suffering from acute drug eruption served as controls. The diagnosis was confirmed by clinical findings and routine histopathology.

Extraction of genomic DNA

Genomic DNA was extracted from paraffin-embedded specimen of skin biopsies taken for diagnostic purposes. After removal of paraffin by extraction with xylene, followed by 2 steps of washing with ethanol, according to a recently described protocol (17), genomic DNA was prepared using a QIAamp Tissue Kit (QIAGEN, Hilden, FRG) according to the manufacturer’s specifications; 100 ng of genomic DNA was used for PCR amplification.

PCR amplification

A 107 bp fragment of the TNF promoter region containing the variable 308 nucleotide was amplified by PCR using the primers as described earlier (6):

Sense primer: 5’-AGGCAATAGGTTTGGAGGGCCAT-3’
Antisense primer: 5’-TCCCTCCCTGCCTCCGATTCG-3’.

The reaction mixture (total volume of 20 µl) contained 4 µM of each primer and 5 units AmpliTaq-DNA Polymerase (Perkin Elmer, Weiterstadt, Germany). The cycling conditions were as follows: an initial denaturation step at 94°C for 5 min was followed by 40 cycles of denaturation at 94°C for 1 min, annealing at 64°C for 1 min and primer extension at 72°C for 1.5 min. A final primer extension step of 10 min at 72°C was added.

NcoI restriction enzyme digest

The amplified PCR product was concentrated by ethanol precipitation after phenol chloroform extraction, digested with 1.5 units NcoI restriction enzyme (Boehringer Mannheim, Mannheim, FRG) at 37°C for 1 h and analysed on a 4% agarose gel (FMC NuSieve 3:1 Agarose, Biozym, Hess. Oldendorf, FRG). The DNA was visualized by ethidium bromide staining. With the TNF A I promoter the sense primer resulted in the generation of a NcoI restriction site which was used for analysis of the PCR product by restriction enzyme digest. The PCR fragment of the TNF A II promoter remained unaffected after restriction enzyme digest. After NcoI digest the PCR product of the TNF A I allele generated two fragments of 87 bp and 20 bp, the TNF A II allele only one fragment of 107 bp, and the heterozygous allele TNF A I/II three fragments of 107 bp, 87 bp and 20 bp.

Statistical analysis

The χ² test with Yates correction was used to determine the significance of differences in TNF-α genotype distribution between patients with EN and patients suffering from EN and sarcoidosis (Loefgren syndrome) and controls.

RESULTS

Fig. 1 shows NcoI restriction enzyme digests of PCR products of the TNF promoter from patients suffering from Loefgren syndrome and drug eruption, respectively. In patients with drug eruption (Fig. 1a) NcoI digest resulted in a 87 bp band (lane 1 and 3). In Loefgren syndrome two clear-cut bands (107 and 87 bp) were detectable in one patient (Fig. 1b; lane 1), while all others showed one band at 107 bp (Fig. 1b; lane 3). Lanes 2 and 4 served as controls and show PCR products (107 bp band) without addition of NcoI.

The distribution of TNF-α genotypes in patients with EN and controls is shown in Table I. The group of patients suffering from EN and pulmonary sarcoidosis (n=10) showed the following distribution of genotypes (Table I): 80% of the individuals were homozygous for the allele TNF A II, 10% were homozygous for TNF A I and 10% were heterozygous for TNF A I/II. This resulted in a TNF A II allele frequency of 0.85.

In EN of other aetiology (n=10), the rare homozygous genotype TNF A II was detected in 20%, the heterozygous gene TNF A I/II in 10%, and the homozygous gene TNF A I in 70%. The frequency of the TNF A II allele in EN patients was 0.25. The differences in allele frequencies of the TNF A II allele between Loefgren syndrome and erythema nodosum of other aetiology were statistically highly significant (p=0.000047) as were the differences of the allele frequencies between Loefgren syndrome and drug eruption (p=0.000007).

In the control groups, the distributions were similar to those of healthy individuals (18). In the granuloma annulare group (n=5) no TNF A II homozygous was found, 80% were homozygous for the TNF A I and 20% were heterozygous, resulting in an allele frequency of 0.10 for TNF A I. In patients suffering from drug eruption (n=12), we observed no homozygous TNF A II allele, 75% were homozygous for TNF A I and 25% were heterozygous. This corresponds to an TNF A II allele frequency of 0.125.

In conclusion, the presented data provided evidence that
The presence of the TNFAII gene might serve as a prognostic parameter to predict sarcoidosis as an underlying disease in EN patients, since the allele frequency in EN patients without associated sarcoidosis was similar to normal controls. In the presence of the TNFAII allele careful follow-up of patients suffering from EN should be undertaken for early detection of systemic sarcoidosis.

ACKNOWLEDGEMENT

This work was supported by the Fritz Thyssen Stiftung, Grant No. 1998 2060.

REFERENCES


**Table I. Tumour necrosis factor-alpha promoter polymorphism (−308): distribution of TNFA alleles**

<table>
<thead>
<tr>
<th>Erythema nodosum</th>
<th>TNFA I</th>
<th>TNFA II</th>
<th>Allele frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Homozygous</td>
<td>10</td>
<td>7 (0.7)*</td>
<td>0.75/0.25*</td>
</tr>
<tr>
<td>Heterozygous</td>
<td>1</td>
<td>1 (0.1)</td>
<td>0.85**</td>
</tr>
<tr>
<td>Homozygous</td>
<td>1</td>
<td>(0.1)</td>
<td>0.90/0.10</td>
</tr>
<tr>
<td>Drug eruption</td>
<td>12</td>
<td>9 (0.75)</td>
<td>0.875/0.125**</td>
</tr>
</tbody>
</table>

*Genotype frequencies are shown in parenthesis.

Differences in TNFAII allele frequencies were statistically highly significant (*p=0.00047; **p=0.000007).

−308 polymorphism is strongly associated with sarcoidosis-associated EN.

**DISCUSSION**

The present report provides evidence for an association between sarcoidosis and EN (Loefgren syndrome) and the uncommon TNFAII allele. Interestingly, EN of other aetiology showed no correlation with the TNFAII allele. In these patients, the allele frequencies were comparable with those of normal controls. Similarly, granuloma annulare, another granulomatous disease of the skin, and acute drug eruption, which served as controls, showed a TNFAII allele frequency comparable to that observed in a healthy population.

In a recent study, the allele frequencies of the TNF-α gene were investigated in a series of patients suffering from pulmonary sarcoidosis and a strong, although less pronounced, association of the TNFAII allele with Loefgren syndrome was found (18). The TNFAII allele frequency was 0.41 for Loefgren syndrome compared to the sarcoidosis group, showing an allele frequency of 0.23. Due to these and the findings of our study, it was of particular interest as to whether the TNFAII promoter is a hallmark of the acute exacerbation of sarcoidosis presenting as Loefgren syndrome, or a characteristic feature of EN itself. Although EN shows some clinical, and at late stage also some histopathological, features of a granulomatous diseases (19), the allele frequency of the TNFAII was not increased in EN of other aetiology. This clearly argues against a genetic basis of this disease. However, not linked to genetic alterations, it is very likely that enhanced TNF-α production might play a role in EN. We have recently found that polymorphonuclear granulocytes are highly activated in EN and show a dramatically enhanced production of reactive oxygen intermediates (20) and it is well known that TNF-α is a potent inducer of reactive oxygen intermediates (21).

A binding motif for a particular transcription factor that could account for enhanced gene expression of TNF-α in TNFAII homozygous patients has not yet been identified. But we recently showed that this region (−308) might play a role in the control of the TNF promoter, at least after stimulation with the activated Raf kinase (22). It had also been shown by other groups that individuals homozygous for the TNFAII allele have higher levels of TNF-α than TNFAI homozygotes (23). These findings had been confirmed by in vitro studies showing enhanced TNF-α promoter activity in TNFAII reporter gene assays (7, 8).

Due to the constant finding of TNFAII homozygous gene expression in Loefgren syndrome, the presence of the TNFAII allele might serve as a prognostic parameter to predict sarcoidosis as an underlying disease in EN patients, since the allele frequency in EN patients without associated sarcoidosis was similar to normal controls. In the presence of the TNFAII allele careful follow-up of patients suffering from EN should be undertaken for early detection of systemic sarcoidosis.


